Resources for your patients
Help your patients connect to these important resources for savings information, support, self-assessment, and more.
Patient portrayal.
Individual results may vary.
Resources
Important resources for your patients, your practice, and you
Help your patients connect to these important resources for savings information, support, self-assessment, and more.
Symptoms of major depressive
disorder, safety information
and the benefits of TRINTELLIX
are explained here.
Connect your patients to
information about savings, support
and more with the tAccess brochure.
Patients can use this
self-assessment tool to help HCPs
understand the nature and severity
of their symptoms.
The TRINTELLIX patient website has
additional tools and resources for
your patients, explaining their
options, and keeping them informed.
Takeda may be able to help patients
without prescription insurance, or
those having difficulty affording
their medications.
Stay prepared and up-to-date with these essential resources.
Used in tandem with the PHQ-9
screener, this card helps HCPs assess
and understand patient symptoms.
Dosage guidance, food restrictions,
and more are all explained on this card.
These tools may help your patients and practice get ready for effective telehealth visits.
This brochure may help patients
prepare for their next telehealth
appointment.
This toolkit is an ever-growing
resource helping HCPs learn more
about telepsychiatry.
An informative guide to real-time
communication tools, remote patient
monitoring, and more.
What to explore next?
Support for
your patients
We’re here to help your eligible patients get the treatment you prescribe.
Safety profile
See how the safety profile fits in the story.
Prescription
savings for your
eligible patients
Find out about savings and support offered through tAccess by reading the Savings Card brochure.
Telling patients
about telehealth
As telehealth visits become more common, it’s important to have helpful resources for you and your patient.
Helping patients access savings info and support
Discover resources that may help your patients with savings and more.
Long-term
clinical data
Results from multiple clinical studies of TRINTELLIX.
Offering
patients once
daily dosing
Learning about dosage amounts and drug interactions.
Request a
rep visit
Connect with a TRINTELLIX representative.
Patient coverage
in your area
Find out about formulary coverage in your area for TRINTELLIX.
Patient profile
Learn more about a patient
living with MDD.
WARNING: SUICIDAL THOUGHTS & BEHAVIORS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most commonly observed adverse reactions for TRINTELLIX in 6- to 8-week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation, and vomiting.
DRUG INTERACTIONS
Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX.
PREGNANCY
Exposure to serotonergic antidepressants, including TRINTELLIX, in late pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to TRINTELLIX in the third trimester for PPHN and drug discontinuation syndrome.
TRINTELLIX is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Please click for Full Prescribing Information.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at
WARNING: SUICIDAL THOUGHTS & BEHAVIORS
CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most commonly observed adverse reactions for TRINTELLIX in 6- to 8-week placebo-controlled studies (incidence ≥5% and at least twice the rate of placebo) were: nausea, constipation, and vomiting.
DRUG INTERACTIONS
Concomitant administration of TRINTELLIX and strong CYP2D6 inhibitors or strong CYP inducers may require a dose adjustment of TRINTELLIX.
PREGNANCY
Exposure to serotonergic antidepressants, including TRINTELLIX, in late pregnancy may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding, and/or persistent pulmonary hypertension of the newborn (PPHN). Monitor neonates who were exposed to TRINTELLIX in the third trimester for PPHN and drug discontinuation syndrome.
TRINTELLIX is indicated for the treatment of Major Depressive Disorder (MDD) in adults.
Please click for Full Prescribing Information.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at